Breast cancer drug 'halves likelihood of high-risk women developing disease'
Anastrozole must be made available on NHS immediately, say charities and authors of trial funded by Cancer Research UKA drug not yet available on the NHS has been found to be better at preventing breast cancer than those approved for use, leading to urgent calls for the National Institute for Health and Care Excellence to make it accessible immediately.The drug anastrozole has been found to halve the likelihood of high-risk women developing the disease and to have fewer side-effects, according to a study published on Thursday in the Lancet medical journal. The Ibis-II study, funded by Cancer Research UK and led by Queen Ma...
Source: Guardian Unlimited Science - December 12, 2013 Category: Science Authors: Alexandra Topping Tags: theguardian.com News Health Society Drugs The National Institute for Health and Care Excellence (Nice) UK news Breast cancer NHS Science Source Type: news
Dr. Timothy J. Garnett
Chief Medical Officer & SVP, Eli Lilly & CompanyDr. Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice-President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director Duloxetine SUI Team; and European...
Source: PHRMA - November 5, 2013 Category: Pharmaceuticals Authors: Leah Source Type: news
Dr. Timothy J. Garnett, FRCOG, MFFP, FFPM
Chief Medical Officer & SVP, Development Center of Excellence, Eli Lilly & CompanyDr. Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice-President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director...
Source: PHRMA - November 5, 2013 Category: Pharmaceuticals Authors: Leah Source Type: news
Task Force issues final recommendations on medications for risk reduction of primary breast cancer in women
The United States Preventive Services Task Force (USPSTF) recommends against using medications such as tamoxifen or raloxifene for reducing the risk of primary breast cancer in average risk women, as the risks associated with these medications outweigh the potential benefits. Doctors should discuss the benefits and harms of these treatments and offer to prescribe them to women who are at high risk for breast cancer and low risk for adverse reactions. In high-risk populations, the benefits may outweigh the risks... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 25, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
New Guidelines on Chemoprevention for Breast CancerNew Guidelines on Chemoprevention for Breast Cancer
The US Preventive Services Task Force (USPSTF) has finalized its guidelines on the use of tamoxifen and raloxifene to prevent breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 24, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Discuss Chemoprevention With Women at Risk for Breast CancerDiscuss Chemoprevention With Women at Risk for Breast Cancer
The US Preventive Services Task Force (USPSTF) has finalized its guidelines on the use of tamoxifen and raloxifene to prevent breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 24, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Experts: Women at high risk of breast cancer should consider 2 drugs
WASHINGTON, Sept. 24 (UPI) -- Women with a higher-than-usual risk for breast cancer should consider taking tamoxifen or the osteoporosis drug raloxifene, a panel of U.S. experts advises. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 24, 2013 Category: Consumer Health News Source Type: news
Who Benefits from Breast Cancer Prevention Drugs? These Genes Might Tell
Researchers matched two gene variations previously unconnected to breast cancer with a positive response to long-term cancer prevention treatment using tamoxifen or raloxifene. Both medications are sometimes given to women who are at high risk of breast cancer, but the drugs can have side effects, including blood clots and increased risk of endometrial cancers. The variants are present in or nearby to genes that affect expression of the gene BRCA1, which is strongly associated with the development of breast cancer. Women with the beneficial version of the two variants were more than 5 times less likely than other high-risk...
Source: NIGMS Biomedical Beat - July 18, 2013 Category: Research Source Type: news
Eli Lilly Freezes Salaries as Patents Expire
Eli Lilly and Company is freezing salaries for most employees in 2014 to reduce costs. Officials said the company would also reduce bonuses paid out in 2015 for 2014 employee performances.
"This is a difficult, but necessary decision. While we remain confident in our future, we continue to face the most significant challenges in our history. We expect to lose about 20 percent of our global revenue in 2014 because of the expiration of the Cymbalta and Evista patents in the U.S. While we've taken many actions to reduce costs and become a leaner organization, we must do more. We estimate these actions will enable us to save...
Source: PharmaManufacturing.com - July 18, 2013 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: news
Doctors can prescribe preventive pill for breast cancer
NICE recommends tamoxifen or raloxifene for up to five years for 'at-risk' women Related items from OnMedicaNew genetic test detects early breast cancerWomen may be offered drug to prevent breast cancerSERMs ward off common breast cancer over long termNICE draft rejects everolimus for advanced breast cancerSecrets of tamoxifen mechanism uncovered (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 26, 2013 Category: UK Health Source Type: news
Chemoprevention of Breast Cancer Recommended in BritainChemoprevention of Breast Cancer Recommended in Britain
The National Institute of Clinical Excellence now recommends using tamoxifen and raloxifene in people at high risk for breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease.
They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older.
The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news
Tamoxifen and raloxifene: Women to be offered daily pill to prevent breast cancer
Hundreds of thousands of women will be prescribed a daily pill that can reduce their risk of getting breast cancer, in what campaigners have called a “game-changing” breakthrough in preventive care. (Source: The Independent - Science)
Source: The Independent - Science - June 24, 2013 Category: Science Tags: Science Source Type: news
Tamoxifen and raloxifene: Daily pill a 'breakthrough' in the prevention of breast cancer
Hundreds of thousands of women will be prescribed a daily pill that can reduce their risk of getting breast cancer, in what campaigners have called a “game-changing” breakthrough in preventive care. (Source: The Independent - Science)
Source: The Independent - Science - June 24, 2013 Category: Science Tags: Science Source Type: news
